Addition of daclatasvir to interferon-based HCV therapy improved treatment response, shortened duration

ID Week, October 2-6, 2013, San Francisco

Addition of daclatasvir to interferon-based HCV therapy improved treatment response, shortened duration
October 9, 2013
SAN FRANCISCO – Patients with hepatitis C treated with daclatasvir in addition to pegylated interferon and ribavirin had better response rates within shorter treatment duration than those who received peginterferon and ribavirin alone in a study presented at ID Week 2013.

Interferon-free regimen safe,effective for patients with HCV genotype 1
October 8, 2013
SAN FRANCISCO – A regimen of daclatasvir, asunaprevir, and a non-nucleoside NS5B inhibitor yielded high sustained virologic response rates among patients with hepatitis C genotype 1 in a study presented at ID Week 2013.